A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies

PCAB (prednisone, cyclophosphamide, doxorubicin, carmustine) is a single-day regimen used for induction and in relapsed/refractory multiple myeloma. This retrospective analysis looked at the outcomes of 85 patients, 30 of whom patients received PCAB with one additional agent (bortezomib most frequently). Analysis showed that PCAB may be considered as a useful salvage therapy among other polychemotherapy regimens in late relapse.